Abstract
We reviewed the results in the literature on chemotherapy with cisplatin and/or other new agents such as etoposide and vindesine in the treatment of non-small cell lung cancer. Associations of cisplatin with vindesine or etoposide have been overall superior to combinations of older cytostatic agents. These combinations result in an average of 30-40% objective response rate with 5% complete responses. High doses of cisplatin seem to be associated with optimal results. Vinblastine, vincristine, bleomycin, methyl-GAG and dihydrogalactitol appear to be promising in combination with cisplatin.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Cisplatin / administration & dosage
-
Cyclophosphamide / administration & dosage
-
Dianhydrogalactitol / administration & dosage
-
Doxorubicin / administration & dosage
-
Drug Evaluation
-
Etoposide / administration & dosage
-
Humans
-
Lung Neoplasms / drug therapy*
-
Prognosis
-
Random Allocation
-
Vinblastine / administration & dosage
-
Vinblastine / analogs & derivatives
-
Vindesine
Substances
-
Bleomycin
-
Dianhydrogalactitol
-
Vinblastine
-
Etoposide
-
Doxorubicin
-
Cyclophosphamide
-
Cisplatin
-
Vindesine